Compare VNCE & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | INTS |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 12.4M |
| IPO Year | 2013 | 2021 |
| Metric | VNCE | INTS |
|---|---|---|
| Price | $4.20 | $4.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.17 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 253.9K | 25.0K |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.45 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $300,007,000.00 | N/A |
| Revenue This Year | $5.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.55 | ★ N/A |
| Revenue Growth | ★ 2.23 | N/A |
| 52 Week Low | $1.19 | $0.19 |
| 52 Week High | $5.90 | $8.06 |
| Indicator | VNCE | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 35.05 |
| Support Level | $4.00 | $0.31 |
| Resistance Level | $4.43 | $8.06 |
| Average True Range (ATR) | 0.47 | 0.21 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 13.54 | 20.24 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.